stars 1 stars 2 stars 3

Curespec, Reducing Blood Pressure Curing the Kidneys A groundbreaking solution that targets chronic kidney disease and hypertension, two critical health challenges affecting over 700 million individuals globally. These conditions drastically reduce the quality of life for those affected. The addressable market for Curespec's solution is substantial, estimated at $16.7 billion across the U.S. and Europe. Our fully developed and CE-marked product leverages Electro-Hydraulic Acoustic Therapy (eHAT) to transform treatment for hypertension and chronic kidney disease. Curespec's innovative therapy reduces blood pressure and enhances kidney function by rejuvenating renal tissue to promote kidney health. Clinical data reveal that 90% of patients maintain their eGFR levels or lower their blood pressure by at least 5 mmHg. The therapy is noninvasive and painless, ensuring patient safety and comfort. Curespec is a paradigm shift in managing hypertension and chronic kidney disease, bringing hope to millions of individuals worldwide. We invite you to join us in this journey by contacting us or visiting our website. https://www.curespec.info/

Curespec Questions

Rotem Kaynan is the CEO of Curespec.

4 people are employed at Curespec.

Top Curespec Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users